Jayanthi Vijayakumar
Medical Oncology · St Louis Park, MNNPI 1598025314
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $75 of the $106 with a category attached, or 70.5%. Boston Scientific accounts for 70.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $75, 3.9 times the $19 reported in 2020. That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.
Across 3 payments — averaging $35.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$75
- E.r. Squibb & Sons, L.L.C.$19
- Gilead$12
Across 64 payments — averaging $5092.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biontech SE$284K
- Pfizer$42K
What the payments were for
- Food & beverage$7571%
- Education$3129%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 1 | $75 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Gilead | 1 | $12 |
How this compares
$106 in reported general payments places this provider in the 20th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 13 | $259,936 |
| Lenalidomide | 17 | $230,249 |
| JakafiRuxolitinib Phosphate | 11 | $181,813 |
| XtandiEnzalutamide | 12 | $163,880 |
| ImbruvicaIbrutinib | 13 | $147,992 |
| EliquisApixaban | 33 | $40,459 |
| Anastrozole | 173 | $4,382 |
| Abiraterone Acetate | 13 | $1,145 |
| Dexamethasone | 55 | $944 |
| Letrozole | 23 | $733 |
| Acyclovir | 27 | $637 |
| Prochlorperazine Maleate | 30 | $589 |
| Hydroxyurea | 26 | $489 |
| Omeprazole | 16 | $357 |
| Gabapentin | 12 | $355 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in St Louis Park
- Amy KrieMinneapolis$907K
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Noel LaudiCoon Rapids$274K
- Emmanuel AntonarakisMinneapolis$260K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.